Two-thirds of neuroendocrine neoplasms arising in the human body originate from the gastrointestinal system or pancreas. Gastroenteropancreatic neuroendocrine neoplasms are heterogeneous, comprising both well differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). The clinical presentation, molecular characteristics, and behavior are distinct for NETs and NECs. Fine-needle aspiration is an important modality for the primary diagnosis and staging of these neoplasms and can provide information of prognostic and therapeutic significance. Our evolving understanding of neuroendocrine neoplasm biology has led to several iterations of classification. In this review, new concepts and issues most relevant to cytology diagnosis of gastroenteropancreatic neuroendocrine neoplasms are discussed, such as newer detection methods that aid in diagnosis and staging, recent changes in World Health Organization classification, practical issues related to grading these neoplasms on cytology, guidelines for diagnostic reporting, and panels of immunohistochemical stains for the diagnosis of metastasis. The current understanding of genetic and epigenetic events related to tumor development and potential applications for cytology also are presented as they relate to prognostication and recent therapeutic advances. Cancer Cytopathol 2018;126:980-991.
Cancer Cytopathology December 2018 are hypervascular. Other modalities for evaluating the extent of disease exploit the moderate-to-high expression of somatostatin receptors in NETs using radiolabeled somatostatin analogues, such as indium-111 ( 111 In)-pentreotide single-photon emission computed tomography (SPECT)/CT (also called an octreotide scan). Octreotide scans are a sensitive (90%) detection method and have been used for over 20 years. 5 Recently, a newer class of somatostatin analogs labeled with gallium 68 ( 68 Ga) (eg, 68 Ga-DOTATATE [somatostatin analogue tyrosine-3-octreotate labeled with 68 Ga using dodecanetetraacetic acid]) and imaged by positron emission tomography (PET)/CT have demonstrated superiority over older methods. For example, 68 Ga-DOTATATE PET/CT detected 95% of unknown primary tumors and primary and metastatic gastroenteropancreatic NETs compared with 31% detected by 111 In-pentreotide SPECT/CT. 6 Potential benefits of gallium scans include the detection of more lesions, more occult primaries, smaller lesions, and lesions with lower somatostatin receptor expression.
Although tubular gastrointestinal NETs have a higher incidence than pancreatic NETs (panNETs), cytologists less commonly encounter biopsies of the primary, because subepithelial and intramural lesions of the tubular gastrointestinal tract are sampled preferentially by endoscopic ultrasound-guided (EUS) core biopsy instead of cytology methods, such as brushing or fine-needle aspiration (FNA). The diagnostic accuracy of EUS-FNA for subepithelial gastrointestinal lesions is influenced by many factors, including the presence of onsite adequacy, and ranges between 60% and 80%. 7 However, studies of EUS-FNA in this context are heavily weighted toward the diagnosis of gastrointestinal stromal tumors; and, given the rarity of gastrointestinal neuroendocrine neoplasms, these studies typically include very few (if any). Both types of biopsy also are performed for the assessment of duodenal and solid pancreas masses; however, at these sites, FNA is more common, because access with a rigid core-biopsy apparatus is more difficult than with the smaller caliber FNA needle. EUS-FNA has 99% sensitivity and 100% specificity for the diagnosis of panNET. 8 CT-guided FNA may be used in isolation or in conjunction with core biopsy to assess for metastatic neuroendocrine neoplasms to mesentery, liver, or lymph nodes.
CLASSIFICATION
Gastroenteropancreatic neuroendocrine neoplasms are divided into 2 main categories by the World Health Organization (WHO)-poorly differentiated NEC and well differentiated NET-and criteria for their classification are summarized in Table 1 . 9, 10 This terminology for the gastroenteropancreatic system is widely preferred over carcinoid or well differentiated (neuro)endocrine carcinoma, although the term carcinoid is currently retained in the classification of well differentiated thoracic neoplasms. NECs and NETs have major differences in appearance and biology. NECs have high proliferative activity and include small-cell, large-cell, and mixed neuroendocrine and non-neuroendocrine types. Most recently, expert opinion is that grade is not necessary for neuroendocrine carcinomas, because they are all high grade. 11 In contrast, NETs have a 3-tier grading system (grades 1-3) based on proliferative activity (Table 1 ). The grade 3 NET category is 1 of 2 changes introduced by the 2017 WHO Classification of Tumors of the Neuroendocrine System and was based on observations that a well differentiated panNETs can have a mitotic count >20 per 10 high-power fields or a proliferation index >20% and had different responses to platinum-based chemotherapy. 12 Grade 3 panNETs are observed more commonly in liver metastases of progressed disease and have a worse 5-year survival rate (29%) than grade 2 panNETs (62%). 13 The second relatively minor change in the 2017 WHO classification is that the Ki67 index range for grade 1 was changed to <3% from ≤2%. Although a 3-tiered grading of tumors from the 2010 WHO classification system is currently the used for nonpancreatic gastrointestinal neuroendocrine neoplasms (Table 1) , the system will be revised in the anticipated fifth edition of the WHO Classification of Gastrointestinal Tumors, and there is a consensus proposal to extend the same classification framework to neuroendocrine neoplasms of all anatomic sites.
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Whether an NET is functional or nonfunctional is not a component of the morphologic classification. Rather, it is a clinical designation based on whether the individual presents with a clinical syndrome related to tumor hormone production.
GRADING
The classification of well differentiated gastroenteropancreatic neuroendocrine neoplasms includes grade, because it is an established independent prognostic factor. Traditionally, definitive grading is performed on resected tumors, but grading on cytology material, which is the most common method of diagnosis, has demonstrated reliability and now has increased therapeutic relevance, because some investigators have proposed that small, asymptomatic (<2 cm) panNETs may be closely monitored by radiology if they are low grade. 14, 15 Histologic grade also incorporates a mitotic count; however, in cytology, mitotic activity generally is not feasible, because standard counting involves an evaluation of 10 consecutive high-power fields and, cell-block cytology has fragmented tissue and dispersed cells. The use of a validated Ki-67 antibody is crucial for tumor grading on cytology. Factors that vary among laboratories include the initial fixation step (generally alcohol or formalin), antibody clone, and automated staining platform. Demonstrations of dramatic differences in the intensity and percentage staining between different antibodies has underscored the importance of antibody validation and detection systems on cytology specimens. 21 One difficulty in the interpretation of Ki-67 staining is the variable intensity. The Ki-67 protein is expressed in nuclei through all active phases of the cell cycle (G1, S1, G2, and M phases), and there is a marked increase and higher staining intensity during the S phase; therefore, all positive nuclei should be counted, even those with low-intensity staining. 22 Phospho-histone HG3 (PHH3) is another potential marker of proliferation, because it labels nuclei only in late G2 and M phase. Histologic grading on resected NETs using PHH3 can facilitate the identification of Cancer Cytopathology December 2018 mitotic activity hotspots, reduce counting time, and improve reproducibility of the mitotic rate assessment. 23 In the largest study to date, PHH3 outperformed Ki-67 as a predictor of disease-specific and disease-free survival for gastroenteropancreatic NETs. However, PHH3 cutoff levels for grading have not been validated in a large cohort, and it has not been incorporated into classification. 23 Experience is limited in the predictive value of this marker in cytology. 24 
DIFFERENTIATION: CYTOMORPHOLOGY AND THE USE OF IMMUNOHISTOCHEMISTRY
Well versus poor differentiation is a crucial component of neuroendocrine neoplasm classification, because it determines therapeutic management. Most neoplasms can be reliably classified by cytomorphology; however, some neoplasms have ambiguous features, particularly grade 3 NETs and large-cell NECs. 25, 26 In those cases, immunohistochemical stains, clinical history, and genomics can contribute information toward classification. 27 The genomic differences between NETs and NECs are discussed below.
The typical appearance of small-cell type NEC is angulated nuclei, minimal cytoplasm, inconspicuous nucleoli, nuclear molding, coarse hyperchromatic chromatin, apoptosis, and necrosis ( Fig. 1A-C ). Large-cell NEC types have large pleomorphic nuclei, moderate-to-abundant cytoplasm, vesicular nuclei, and prominent nucleoli ( Fig. 1D-F) . Features of small-cell and large-cell NECs may coexist, but therapy is the same. NEC can appear as a component of non-neuroendocrine carcinoma; adenocarcinoma is morphologically distinct, but acinar differentiation requires immunohistochemistry to confirm. Because so-called mixed carcinomas exhibiting immunophenotypic evidence of acinar differentiation have genetic similarity with pure acinar cell carcinomas, identifying this component has clinical significance. 28 Thus, the workup of high-grade intra-abdominal neoplasms (including tumors with advanced presentation) that possess eosinophilic cytoplasm and acinar, rosette-like, or solid architecture should include immunohistochemistry for both neuroendocrine and acinar markers. The cytomorphology of NETs is similar across gastroenteropancreatic sites (Fig. 2) . Grade 1 and 2 NETs Cancer Cytopathology December 2018 produce cellular aspirates and have small, bland, and poorly cohesive epithelioid cells with round-to-ovoid, smoothly contoured nuclei ( Fig. 2A-C) . Plasmacytoid morphology is most common, whereas variants include oncocytic, pleomorphic, and clear-cell/lipid-rich NET (Fig. 2D-F) . Architectural variants of panNETs, such as cystic or sclerosing (serotonin-expressing), have no distinctive cytomorphology. Grade 3 panNETs generally resemble grade 1 and 2 tumors and frequently have plasmacytoid morphology and smooth nuclear membranes; however, there is increased abundant cytoplasm, nuclear tangles, and apoptosis; which are features also observed in NEC (Fig. 2G-I) . 26, 27 Compared with NECs, grade 3 panNETs have more plasmacytoid morphology, round nuclei, and smooth nuclear membranes and less pleomorphism, angulated nuclei, molding, and necrosis. Patterns of immunohistochemical staining can aid in the diagnosis of neuroendocrine neoplasms and the distinction between NET, NEC, and other neoplasms with neuroendocrine differentiation. Synaptophysin and chromogranin A typically are strong and diffuse in extraadrenal paraganglioma and NET, even in grade 3 NET. 12, 29 Pan-cytokeratin labeling is helpful for the differential diagnosis of NET and extra-adrenal paraganglioma, which is negative. Cluster of differentiation 56 (CD56)/neural-cell adhesion molecule and Cancer Cytopathology December 2018
neuron-specific enolase are less specific markers for these neoplasms and are not essential in the panel. 30 Staining for peptide hormones also is not essential, because it has no impact on NET classification. Solid pseudopapillary neoplasm is in the differential diagnosis with NET and can exhibit focal synaptophysin staining, but it should never be positive for chromogranin, and other markers to support solid pseudopapillary neoplasm can be added to the panel, such as β-catenin (nuclear stain) and CD99 (dotlike staining). For NET versus NEC, chromogranin A stains NEC less uniformly and less frequently compared with NET. Insulinoma-associated protein 1 (INSM1) is a specific nuclear marker for neuroendocrine differentiation, but it does not distinguish well versus poor differentiation. 29 Ki-67 proliferation should not be relied upon exclusively to discriminate NET from NEC. Although the median Ki-67 index for NEC is significantly higher (62%) than that for grade 3 NET (40%), the ranges overlap significantly (NEC: range, 25%-95%; grade 3 NET: range, 21%-89%), and Ki-67 indices do not define differentiation. 27 A caveat, however, is that the most highly proliferative neoplasms (>90%), particularly those presenting de novo, are most likely NECs. 13 Trypsin, chymotrypsin, and/or B-cell lymphoma/leukemia 10 (bcl-10) are appropriate to interrogate for acinar differentiation in this differential diagnosis, as mentioned above. Focal neuroendocrine labeling is common in acinar cell carcinomas, but a higher proportion of staining (eg, >30%) raises the possibility of carcinoma with mixed differentiation. Pancreatoblastoma also is in the differential diagnosis of neoplasms with neuroendocrine and/ or acinar differentiation and can rarely present in adults. Pancreatoblastoma is diagnosed by the identification of β-catenin-positive (nuclear labeling), squamoid whorls. Some immunohistochemical stains are available that can be useful to distinguish grade 3 NET from NEC by interrogating for loss of protein expression resulting from genetic mutations. Specifically, the loss of nuclear immunohistochemical staining with retinoblastoma (Rb), death-domain-associated protein (DAXX), and adenosine triphosphatase-dependent helicase ATRX (ATRX) correlate with mutation status in histologic and cytologic studies. [31] [32] [33] [34] NECs of any primary site can have RB1 gene mutations, whereas NETs have not been reported with this mutation. 32, 35 Retained Rb staining does not exclude NEC, because this mutation is present only in a subset of NECs. Some panNETs exhibit loss of nuclear staining for DAXX and ATRX, because mutations are present in the respective genes in up to 45% of panNETs. Retained nuclear staining for these markers is not helpful. Immunohistochemistry for p53 is another candidate marker for this differential diagnosis, because tumor protein p53 (TP53) mutations are common in NEC and are relatively infrequent in NET; however, currently, there is less evidence indicating the appropriate threshold for a positive stain, and the utility is uncertain. 25, 36, 37 Clinical history is helpful for supporting the differentiation of neuroendocrine neoplasms. Grade 3 NETs can (but rarely do) present de novo, and most patients have a known history of grade 1 and 2 NET that may have originated up to 10 years prior. 25 NETs do not progress to NEC, so a documented history of grade 1 and 2 NET supports an NET diagnosis, although changes in morphology may occur. Indeed, heterogeneity of NET morphology and grade at presentation has been documented in de novo grade 3 NETs. 12 In contrast, NEC is so rapidly progressive that patients have poor clinical status on presentation and, clinically, the suspicion for an aggressive malignancy is high.
APPROACH TO METASTASIS
All gastroenteropancreatic neuroendocrine neoplasms that metastasize tend to involve the liver, and cytologists often provide the primary diagnosis and confirm tumor stage. Mesentery, peritoneum, and lymph nodes are other common sites of metastasis, whereas bony metastasis is typically a late occurrence. The diagnostic approach for suspected neuroendocrine metastases involves confirming neuroendocrine derivation and, if indicated, excluding other entities in the differential diagnosis. Next, it is crucial to state whether the neoplasm is well or poorly differentiated, as discussed above. It is also important to understand whether an investigation for site of origin is necessary and, finally, whether tumor grade is relevant. In most scenarios, if a neuroendocrine neoplasm is suspected at the time of rapid on-site evaluation, then a recommendation to collect material for a cell block is advantageous. Confirmation of neuroendocrine derivation is typically straightforward for NETs, because well differentiated tumors generally stain strongly and uniformly for Cancer Cytopathology December 2018 synaptophysin and chromogranin A. In contrast, chromogranin A staining can be reduced in NECs. INSM1 also can be used to define a neoplasm as neuroendocrine. CD56 is often used to investigate for neuroendocrine differentiation in poorly differentiated tumors, but it is much less specific and stains many non-neuroendocrine neoplasms.
The differential diagnosis for metastatic NET includes other epithelioid neoplasms with amphophilic-to-eosinophilic cytoplasm, such as acinar cell carcinoma (well differentiated), metastatic adenocarcinoma (particularly of mammary origin), melanoma, hepatocellular carcinoma, renal cell carcinoma, pheochromocytoma, and rare epitheloid tumors of mesenchymal origin, such as perivascular cell tumor (PEComa), gastrointestinal stromal tumor, or leiomyosarcoma. An immunohistochemical panel for NET with typical morphology often requires only synaptophysin, chromogranin A, pan-cytokeratin, and Ki-67 (for grading). The workup of a proliferative or variant NET likely would include a broader panel chosen with consideration of the clinical history and presentation. The differential diagnosis of NEC in the liver includes adenocarcinoma with neuroendocrine differentiation of origin from various sites, including castrate-resistant prostate adenocarcinoma. Although therapy for NEC is straightforward, the clinical significance of focal neuroendocrine differentiation is of uncertain significance in adenocarcinomas of many sites. The differential diagnosis for NEC also includes metastatic squamous cell carcinoma with basaloid features, mixed neuroendocrine-non-neuroendocrine neoplasms, and acinar cell carcinoma. NEC large-cell type and acinar cell carcinoma are nearly impossible to distinguish without immunohistochemistry. Acinar cell carcinomas have variable proliferation and are in the differential diagnosis of both NET and NEC. An immunohistochemical approach to suspected NEC varies with small-cell and large-cell types but usually includes the same markers as an NET workup, with the addition of Rb, trypsin, chymotrypsin, and/or bcl-10.
For nearly all metastatic NECs, it is not necessary to determine the site of origin, because they are all treated with systemic, platinum-based chemotherapy. 38, 39 The exception to this rule is Merkel cell carcinoma, which has different management and can be investigated for by cytokeratin 20 (CK20) (perinuclear dot-like staining) and/or immunohistochemistry for Merkel cell polyomavirus. Determining a specific site of origin is crucial for well differentiated neuroendocrine neoplasms, because it guides site-specific therapy and affects tumor grading, which is organ-specific. 11, 40 Most NET liver metastases are from gastroenteropancreatic sites. In order from the most common to the least common, NET liver metastases arrive in the liver from primaries in the pancreas (35%), small intestine (27%), colon/rectum (12%), and lung (4%). 41 However, a primary site is not radiologically apparent (without surgery or endoscopy) in 11% to 21% of NETs. 41, 42 In the absence of a primary site, tumors are treated based on clinical and pathologic assessment of aggressiveness. 39 Immunohistochemistry can be applied to determine the site of origin for an NET when it is not identified by clinical methods. Labeling patterns of lung and gastroenteropancreatic tumors are summarized in Table 2 . 38, [43] [44] [45] Transcription factors that label the majority of panNETs include islet 1 (ISL1) and NK2 homeobox 2 (NKX2.2), 43, 44 whereas caudal-type homeobox 2 (CDX2) labeling is rare, and transcription termination factor 1(TTF-1) labeling is negative. 43 CDX2 The ileum was the predominant site of origin for small bowel tumors.
Cancer Cytopathology December 2018 stains most small-bowel NETs but stains only a subset of stomach tumors and possibly no rectal tumors. 43 NKX2.2 stains most gastroenteropancreatic NETs but not lung tumors. In gastrointestinal NETs, ISL1 is only likely to stain rectal tumors. TTF-1 labeling is negative in gastrointestinal NETs. The use of a 3-marker panel (TTF1, CDX2, and ISL1) discriminates small-intestine origin (TTF1-negative, CDX2-positive) from lung origin (TTF1-positive, CDX2-negative) with 89% and 100% positive predictive value, respectively. Positive staining for ISL1 in TTF1-negative/CDX2-negative NETs supports a pancreatic or rectal origin with a positive predictive value of 100%. 43, 44 Markers with limited or no utility for indicating primary site include CK7, CK20, INSM1, pancreatic and duodenal homeobox 1 (PDX1), and NKX2.2. 29,46,47 Paired box 8 (PAX8) also has limited utility for liver metastasis, because various clones stain NETs from a wide range of sites above and below the diaphragm. 43, 48 In addition to immunohistochemistry, some gene-expression profiling assays have been developed for predicting neuroendocrine tumor site of origin. 49, 50 Grade should be reported for metastatic gastroenteropancreatic NETs, because increases in grade between primary and metastatic NETs have been correlated with decreases in progression-free and overall survival. 51 When evaluating metastatic neoplasms, an increase in grade does not change the differentiation category.
DIAGNOSTIC REPORTING OF NEUROENDOCRINE NEOPLASMS IN CYTOLOGY
The pancreas is among the growing number of anatomic sites for which a system for reporting cytology diagnosis has been developed. 52 The 2014 Papanicolaou Society of Cytopathology System places NET in category IV: neoplastic: other When cytologic features of this tumor are limited and a definitive diagnosis cannot be reached, category III: atypical is recommended instead of category V: suspicious, because the latter category is intended only for suspicion of uniformly aggressive cancers. Category VI: positive or malignant is used for reporting NEC unless evidence is limited, and then category V: suspicious is used. This system is not without controversy, given the understanding that all neoplasms >0.5 cm have malignant potential; however the system does facilitate conservative management for certain low-risk tumors. It was developed for pancreatobiliary specimens, and the categorization of metastasis is not explicitly covered. For metastatic NETs, the neoplastic: other category could be used for consistency; however, in our opinion, a positive/ malignant category also could be appropriate for a biopsy of advanced disease. For other gastrointestinal primaries, there is no cytology reporting system, and the paradigm for the pancreas could be used as a model. Providing a WHO grade, as discussed above, is clinically relevant for all primary and metastatic gastroenteropancreatic NETs.
GENETICS
Next-generation sequencing of cytology specimens that contain neuroendocrine neoplasms demonstrates genotypes similar to those identified in histologic studies. 36, 37 The most common somatic mutations of panNECs are TP53, v-Ki-Ras2 Kirsten rat sarcoma 2 viral oncogene (KRAS), phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3) catalytic subunit α/phosphatase and tensin homolog (PIK3CA/PTEN ), and B-raf proto-oncogene serine threonine kinase (BRAF). Other mutations occurring at a lower frequency include RB1, cyclin-dependent kinase inhibitor 2A (CDKN2A/p16 ), adenomatous polyposis coli (APC), F-box and WD repeat domain-containing 7 (FBXW7), WNT, BCL2, and catenin β1 (CTNNB1). 32, 53 PanNETs have recurring genetic alterations that do not occur in panNECs. Overall, in panNETs, the main genetic pathways affected are DNA damage repair, chromatin remodeling, telomere alteration, and activation of the PI3K/ mammalian target of rapamycin (PI3K/mTOR) signaling pathway. The most common recurrent genetic mutations are multiple endocrine neoplasia type 1 (MEN1) (42%-45%), DAXX (11%-25%), and ATRX (10%-18%). 31, 32, 36, 37 Mutations in the mTOR pathway genes tuberous sclerosis complex 2(TSC2) (8%), PTEN (7%), and PIK3CA (1%) also are observed in panNETs. Germline mutations of MEN1, von HippelLindau tumor suppressor (VHL), cyclin-dependent kinase inhibitor 2B (CDKN1B), mutY DNA glycosylase (MUTYH), checkpoint kinase 2 (CHEK2), and BRCA have been reported in neuroendocrine tumors. 54 Germline mutations even may be present in up to 17% of patients without a family history of cancer. Although no clear, targetable driver mutations have been identified for panNETs, detecting the presence of Cancer Cytopathology December 2018 DAXX and ATRX mutations is of clinical interest, because they are predictors of a poor prognosis. 33, 36, [55] [56] [57] [58] The functional significance of ATRX and DAXX gene products is the regulation of histone deposition in pericentromeric and telomeric chromatin assembly. These genes also interact with chromatin remodeling and modulation of PTEN, which is a component of the mTOR pathway. DAXX/ATRX mutations may occur late in tumor development, because they are observed in higher stage tumors. 33, 55 When there are DAXX/ATRX alterations, alternative lengthening of telomeres (ALT) also occurs, which can be detected by telomere-specific fluorescent in situ hybridization. 31 The loss of DAXX/ ATRX expression and the detection of ALT are negative, independent prognostic factors for disease-free survival.
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DAXX and ATRX mutations are correlated with loss of expression of their respective nuclear proteins by immunohistochemistry, as discussed above. Although heterogeneous expression for these markers has been demonstrated in resected tumors, DAXX/ATRX immunohistochemistry and ALT fluorescent in situ hybridization have revealed complete concordance between resection specimens and formalin-fixed cell-block material prepared from FNAs. 33, 34 ALT also can be detected in tumors with retained DAXX and ATRX nuclear protein expression. 33, 58 Compared with panNETs, NETs of the small bowel lack recurrent mutations. The most frequent genetic mutation is CDKN1B, but is only present in 8% of tumors and does not correlate with the expression of the gene's protein product p27. 59 Other mutated genes include MEN1, VHL, fibroblast growth factor receptor 2 (FGFR2), and BRAF. 60 The PI3K/Akt/mTOR pathway is the most common altered pathway, with alterations present in 33% of small-bowel neuroendocrine tumors. 60 
EPIGENETICS
Epigenetic alterations are of general interest in tumor biology, because they can drive tumorigenesis, even preceding the mutation of cancer-driving gene mutations. These alterations are considered a possible therapeutic target, because they potentially may be reversible. 61 The pursuit of understanding of the epigenetic patterns of NETs is motivated by the lack of classic genetic drivers of cancer, such as KRAS or p53. In the case of panNETs, the function of the 3 most commonly mutated genes (MEN1, DAXX, and ATRX ) is epigenetic regulation. Epigenetic modifications also have emerged as playing a key role in the pathogenesis of gastrointestinal NETs, which lack recurrent mutations but have high-frequency epigenetic dysregulation.
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DNA methylation is the most studied epigenetic change in gastroenteropancreatic NETs. Methylation patterns may help indicate sites of neuroendocrine tumor origin and potentially prognosticate within those groups. Genes with frequent DNA hypermethylation in panNETs include Ras association domain family member 1 (RASSF1), CDKN2A/P16INK4a, TIMP metallopeptidase inhibitor 3 (TIMP3), VHL, O-6-methylguanine-DNA methyltransferase (MGMT ), and pleckstrin homology-like domain family A member 3 (PHLDA3), several of which have prognostic significance (for review, see Karpathakis and colleagues). 62, 63 Small-bowel NETs are highly epigenetically dysregulated and demonstrate different patterns of methylation compared with panNETs. Genes with frequent (>40%) DNA hypermethylation that present in patterns distinctive for gastrointestinal NET include RASSF1, CDKN2A/P16INK4a, CTNNB1, P14, thrombospondin 1 (THBS1), Wilms tumor 1 (WT1), and cadherin-1 (CDH1). 62 Integrated molecular analysis, including epigenetic markers, of small-bowel NETs has identified potential subtypes with differential survival. 59 
SURVIVAL AND THERAPEUTIC ADVANCES
The survival of patients with NETs has improved over the past 2 decades because of therapeutic advances. 1, 61, 64 The survival rate for those who have nonfunctioning panNETs after undergoing resection ranges from 65% to 86% at 5 years and from 45% to 68% at 10 years. 65, 66 Patients who have high-stage, grade 1 or 2 NETs at presentation have a 5-year survival rate of 50%. The 5-year survival rate for those who have high-stage, grade 1 or 2 NETs of the small intestine is 69%. 67 Therapy for NEC and NET is vastly different. Platinum-based therapy remains the mainstay of therapy for NEC, but survival is poor. In contrast, surgical resection is performed both as a curative approach for patients with early stage disease and as a first-line treatment for Cancer Cytopathology December 2018 the small subset of patients (5%-20%) who have metastatic gastroenteropancreatic NETs, in which up to 90% of disease can be resected. 68 Foremost in use are the somatostatin analogues, which control symptoms, slow tumor progression, and increase survival. 69 Octreotide and lanreotide are the most common agents, whereas telotristat ethyl is newer but only controls symptoms. Sunitinib (a vascular endothelial growth factor inhibitor) and everolimus (an mTOR inhibitor) have US Food and Drug Administration approval after demonstrating that it decreased the probability of tumor progression in panNETs. 70, 71 Capecitabine combined with temozolomide (an alkylating agent) is used to treat patients with aggressive panNETs, but midgut NETs have not had the same responses to these agents. 69 Peptide receptor radionuclide therapy combines a somatostatin analog with a β-emitting radioisotope (eg, lutetium 177-dototate) and is being evaluated in randomized controlled trials. 72 Progressive disease may be treated with liver embolization or selective internal radiation therapy. Immunotherapy is not well studied for these tumors. In summary, the selection and sequence of nonsurgical treatment includes consideration of tumor functional status, grade, extent of disease and growth rate, somatostatin uptake, and various patient-related factors. 69 Further investigations to identify predictive biomarkers that can aid in predicting therapeutic response and assessing tumor progression are necessary. 64 
CONCLUSION
Significant progress in understanding the biologic basis of neuroendocrine neoplasms has led to improvements in our approach to the classification, reporting, and treatment of gastroenteropancreatic neuroendocrine neoplasms over the last few decades. Genotyping these neoplasms can aid in diagnosis, potentially predict behavior, and guide therapy, particularly with regard to agents affecting the mTOR pathway. Cytology is known to be highly accurate for diagnosis and staging of these neoplasms, but it is also a highly effective, nonoperative technique for acquiring concentrated cellular tumor samples with well preserved genetic material that can be used successfully for next-generation sequencing. 37 Areas of opportunity for further advancement in cytology in the field of gastroenteropancreatic neuroendocrine neoplasms include validation of surrogate markers for NET genotype and investigation into the potential role of cytology in assessing for emerging epigenetic modifications and biomarkers with potential prognostic and/or therapeutic importance.
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